It's been a week notable for developments in neurology medicine, with Celgene exercising an option to buy a potential multiple sclerosis drug, as GW Pharma prepares a filing for a phase 3 epilepsy drug derived from the cannabis plant.
Celgene has exercised a $20 million option to obtain ex-US...